Minoxidil Dose Response Study in Females Identified Through IVD Testing as Non-Responders to 5% Topical Minoxidil
Status:
Withdrawn
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
5% topical minoxidil is the maximum dosage approved by the US FDA for the treatment of female
pattern hair loss. While topical minoxidil exhibits a good safety profile, the efficacy in
the overall population is relatively low i.e., 30-40% re-grow hair.
The primary purpose of this study is to assess if a higher dosage of topical minoxidil dosage
(15%) will increase the number of responders among female subjects that have been identified
through IVD testing as non-responders to 5% topical minoxidil.